Waaseth Marit, Eggen Anne Elise, Grimsgaard Sameline
Institute of Community Medicine, University of Tromsø, NO-9037, Tromsø, Norway.
Pharm World Sci. 2007 Jun;29(3):137-45. doi: 10.1007/s11096-006-9033-7. Epub 2007 Feb 10.
to quantify sales of authorized natural remedies (ANRs) in Norway, to compare the Norwegian authorization scheme with similar schemes in Sweden, Denmark and the EU, and to identify factors influencing the number of marketed ANRs.
descriptive statistics are used to present sales of ANRs in Norway. The ANRs are classified by indication group and assigned a recommended daily dose (RDD) according to the posology section in the Summary of Product Characteristics (SPC). Document analysis of regulation and general information concerning natural remedies is used to compare the authorization schemes for ANRs in Scandinavia and for traditional herbal medicinal products (THMs) in the EU. Four cases of herbs are described to illustrate the consequences of this regulation and identify possible influencing factors.
sales, in terms of both mean consumer prices and number of RDDs, and the factors found to influence the number of marketed ANRs.
total sales of ANRs in Norway in 2003 were
sales of authorized compared to unauthorized natural remedies in Norway are very low and the ANRs are in a weak position compared to Denmark and Sweden. Surveillance by health authorities and increased consumer knowledge of ANRs is probably more stimulating with respect to application incentive than lower application costs. Introducing THMs will hopefully increase the number of quality-controlled products on the Scandinavian market.
量化挪威授权天然药物(ANR)的销售额,将挪威的授权方案与瑞典、丹麦及欧盟的类似方案进行比较,并确定影响上市ANR数量的因素。
采用描述性统计方法呈现挪威ANR的销售额。ANR按适应症分组,并根据产品特性摘要(SPC)中的剂量说明部分指定推荐日剂量(RDD)。通过对天然药物相关法规和一般信息的文献分析,比较斯堪的纳维亚半岛ANR的授权方案与欧盟传统草药产品(THM)的授权方案。描述了四个草药案例,以说明该法规的后果并确定可能的影响因素。
以平均消费者价格和RDD数量衡量的销售额,以及发现的影响上市ANR数量的因素。
2003年挪威ANR的总销售额为人均1.5欧元(占食品补充剂市场的3%),或5.5 RDD/1000/天,且销售额呈下降趋势。与瑞典和丹麦相比,挪威的ANR非常少。2004年挪威ANR法规的变化使斯堪的纳维亚半岛的申请要求趋于一致,但结果尚未显现。THM与ANR的质量要求相同,并将在未来7年内取代ANR。有几个因素影响了制造商的申请积极性,例如申请成本、差异化增值税率、消费者知识以及卫生当局的监管。
与未经授权的天然药物相比,挪威授权天然药物的销售额非常低,与丹麦和瑞典相比,ANR处于弱势地位。卫生当局的监管以及消费者对ANR知识的增加,在申请激励方面可能比降低申请成本更具刺激性。引入THM有望增加斯堪的纳维亚市场上质量受控产品的数量。